A new vaccination strategy designed to induce antibodies that recognize the apex of the HIV Env protein uses Env trimers displayed on liposomes to increase their density and orient them correctly. This presentation enhanced apex-focused antibody responses in macaques, and the monoclonal antibodies isolated after immunization showed binding modes and structural features resembling human broadly neutralizing antibodies (bNAbs), indicating that the vaccine can steer the antibody response toward this vulnerable site.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Curocell, Emergent, GSK, Newron, Orchard, Orchestra, OS, Prolong, Uniqure, Xbrane.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune,Aptose, Astrazeneca, Bioreference Health, Cardioline, Cardios, Filament Health, Guardant, Maxxspine Innovative, Mintneuro, Motif, Nuvalent, Osartis, OSR, Pinetree, Red Light Holland, Takeda, Vaximm, Wellspect.
Clinical updates for biopharma and med tech, including data readouts and publications: Agendia, Alector, Can-Fite, Edap TMS, Novo Nordisk, Renibus, Telix, TLC.
New hires and promotions in the biopharma and med-tech industries, including: Avita Medical, Halozyme, Johnson & Johnson, Microbot Medical, Proqr, Sanofi, Sonablate, Teleflex.
A month ahead of its June 5 PDUFA date, Arvinas Inc.’s vepdegestrant gained U.S. FDA approval for use in a specific type of advanced or metastatic breast cancer, becoming the first proteolysis targeting chimera, or PROTAC, drug to reach the market.
RSS
